Purpose This work proposes a theoretical framework that enables comparative risk predictions for second cancer incidence after particle beam therapy for different ion species for individual patients, accounting for differences in relative biological effectiveness (RBE) for the competing processes of tumor initiation and cell inactivation. Our working hypothesis was that use of carbon-ion therapy instead of proton therapy would show a difference in the predicted risk of second cancer incidence in the breast for a sample of Hodgkin lymphoma (HL) patients. Methods and Materials We generated biologic treatment plans and calculated relative predicted risks of second cancer in the breast by using two proposed methods: a full model derived from the linear quadratic model and a simpler linear-no-threshold model. Results For our reference calculation, we found the predicted risk of breast cancer incidence for carbon-ion plans-to-proton plan ratio, , to be 0.75 ± 0.07 but not significantly smaller than 1 (P=.180). Conclusions Our findings suggest that second cancer risks are, on average, comparable between proton therapy and carbon-ion therapy.
Publication Source (Journal or Book title)
International Journal of Radiation Oncology Biology Physics
Eley, J., Friedrich, T., Homann, K., Howell, R., Scholz, M., Durante, M., & Newhauser, W. (2016). Comparative Risk Predictions of Second Cancers after Carbon-Ion Therapy Versus Proton Therapy. International Journal of Radiation Oncology Biology Physics, 95 (1), 279-286. https://doi.org/10.1016/j.ijrobp.2016.02.032